Aster DM Quality Care Limited completes QCIL merger, adds 353.55m shares

Aster DM Quality Care Limited completed its merger with Quality Care India Limited on 1 July 2026 and allotted 353.551 million fully paid shares on 13 July 2026. Aster DM Quality Care included Quality Care India Limited's results only for 1 July to 30 September, meaning earlier reported periods were not restated and are not comparable.

When did Aster DM Quality Care complete the QCIL merger?

Aster DM Quality Care completed the merger with Quality Care India Limited, or QCIL, with effect from 1 July 2026. The National Company Law Tribunal sanctioned the scheme on 19 June 2026, and the applicant companies filed approvals and other documents with the Registrar of Companies, Telangana, on 26 June 2026 before the scheme became effective.

The scheme transferred all QCIL assets, liabilities and reserves to Aster DM Quality Care and changed the listed company's name from Aster DM Healthcare Limited. Aster DM Quality Care applied the pooling-of-interests method under Indian Accounting Standard 103, or Ind AS 103, Business Combinations, to account for the amalgamation.

How many shares did Aster DM Quality Care issue for QCIL?

Aster DM Quality Care allotted 353,551,410 fully paid equity shares of face value Rs 10 each to former QCIL shareholders on 13 July 2026. The shares were issued under the exchange ratio set out in the scheme to QCIL shareholders on the record date.

The allotment raised paid-up equity share capital by Rs 353.55 crore, to Rs 871.68 crore at 30 September 2026 from Rs 518.13 crore at 30 June 2026. The nominal-capital increase corresponds to the 353.551 million shares issued at Rs 10 each.

Standalone total equity was Rs 7,519.13 crore at 30 September 2026, against Rs 4,366.22 crore at 31 March 2026. Consolidated total equity was Rs 9,229.49 crore, compared with Rs 4,833.70 crore at 31 March 2026, although the filing does not assign each balance-sheet movement separately to the amalgamation.

Are Aster DM Quality Care's September results comparable with earlier periods?

No, Aster DM Quality Care states that the quarter and six-month results ended 30 September 2026 are not comparable with the preceding quarter or prior-year periods. QCIL results entered both standalone and consolidated reporting only from 1 July 2026 to 30 September 2026, while earlier figures were not restated.

Consolidated revenue from operations was Rs 2,829.20 crore for the September 2026 quarter, compared with Rs 1,310.68 crore in the June 2026 quarter and Rs 1,197.21 crore in the September 2025 quarter. Consolidated profit was Rs 322.38 crore, against Rs 29.28 crore in June 2026 and Rs 121.31 crore a year earlier, but these are not like-for-like movements because the latest quarter includes QCIL.

For the six months ended 30 September 2026, consolidated revenue from operations was Rs 4,139.88 crore and profit was Rs 351.66 crore, versus Rs 2,275.08 crore and Rs 214.87 crore respectively a year earlier. The group reported Rs 133.33 crore of exceptional merger-related costs during the latest six-month period, including professional fees and other transaction costs.

Standalone revenue from operations was Rs 1,204.21 crore in the September quarter, compared with Rs 725.73 crore in June 2026 and Rs 681.81 crore in September 2025. Standalone profit was Rs 106.15 crore, versus a Rs 14.30 crore loss in June 2026 and Rs 104.61 crore profit a year earlier; standalone merger-related exceptional costs were Rs 14.23 crore for the quarter.

Which segments generated Aster DM Quality Care's September revenue?

Hospitals & Clinics generated Rs 2,772.84 crore of September-quarter segment revenue, while Others generated Rs 112.91 crore. After eliminating Rs 56.55 crore of inter-segment revenue, Aster DM Quality Care reported consolidated revenue from operations of Rs 2,829.20 crore.

Hospitals & Clinics recorded segment results before tax, exceptional items and finance cost of Rs 544.64 crore, compared with Rs 13.01 crore for Others. Total segment results of Rs 557.65 crore were reduced by Rs 118.98 crore of finance cost, Rs 8.00 crore of equity-accounted investee losses and Rs 11.32 crore of other unallocated expenditure net of income.

Aster DM Quality Care revised its segment classification in the September 2026 quarter, regrouping Labs and Pharmacies under Others. The group now reports Hospitals & Clinics and Others as its two reportable segments, and it reclassified comparative figures to reflect the new presentation.

Hospitals & Clinics held Rs 16,315.36 crore of segment assets at 30 September 2026, compared with Rs 453.45 crore for Others and Rs 753.98 crore of unallocated assets. Consolidated assets totalled Rs 17,522.79 crore at 30 September 2026, up from Rs 8,111.96 crore at 31 March 2026, during the period in which QCIL joined the group.

What other ownership changes did Aster DM Quality Care report?

Aster DM Quality Care acquired an additional 9.00% stake in United Ciigma Institute of Medical Sciences Private Limited for Rs 30.69 crore on 10 September 2026. Its ownership increased from 76.00% on 1 July 2026 to 85.00% at 30 September 2026.

A subsidiary acquired a further 14.21% in STS Holdings Limited from minority shareholders for Rs 495.23 crore on 18 August 2026. The group's holding in STS Holdings increased from 60.12% at 1 July 2026 to 74.33% at 30 September 2026.

The consolidated cash-flow statement recorded Rs 559.39 crore for acquisitions of non-controlling interests in the six months ended 30 September 2026, compared with Rs 66.43 crore a year earlier. Cash and cash equivalents were Rs 776.15 crore at 30 September 2026, including Rs 410.49 crore added through the amalgamation, versus Rs 228.07 crore at the start of the period.

Conclusion

The QCIL merger has changed Aster DM Quality Care's equity base, reporting perimeter and financial scale. The 353.551 million-share allotment lifted paid-up share capital to Rs 871.68 crore, while the September-quarter consolidated results include QCIL for only three months and cannot be directly compared with the June quarter or prior-year periods.

The key reporting issue to watch is how Aster DM Quality Care presents future post-merger periods while the pre-1 July 2026 figures remain unrestated. The company also has an approved employee stock option scheme, approved by shareholders on 26 September 2026, alongside the newly increased ownership stakes of 85.00% in United Ciigma Institute of Medical Sciences and 74.33% in STS Holdings.